Page last updated: 2024-08-24

glucose, (beta-d)-isomer and Diabetic Ketoacidosis

glucose, (beta-d)-isomer has been researched along with Diabetic Ketoacidosis in 58 studies

Research

Studies (58)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	36 (62.07)	24.3611
2020's	22 (37.93)	2.80

Authors

Authors	Studies
Kainz, M; Schiferer, A; Tschernko, E; Wohlrab, P; Zapletal, B	1
Abu Shamsi, MY; Ismail, I; Kamaruddin, NA; Sukor, N; Wan Azman, SS	1
Chepulis, L; Paul, R; Yu, A	1
Bardhi, O; Bloom, MD; Sattari, M	1
Aktas, G; Bilgin, S; Duman, TT; Kurtkulagi, O; Yilmaz, F	1
Dong, L; Li, H; Li, Y; Lin, D; Lou, P; Ma, L; Wang, K; Xu, L; Zang, D	1
Alduraibi, RK; Alrebdi, YM; Altowayan, YF	1
Cowen, J; Leader, R; Rajeev, SP	1
Asada, K; Ide, N; Ito, M; Kitajima, S; Matsushima, S; Obayashi, M; Yamamoto, M	1
Cho, H; Park, JH; Seo, I; Shim, HM	1
Bhatt, DL; Cahn, A; Fredriksson, M; Gause-Nilsson, IAM; Goodrich, EL; Johansson, PA; Langkilde, AM; Leiter, LA; McGuire, DK; Mosenzon, O; Murphy, SA; Raz, I; Rozenberg, A; Sabatine, MS; Wilding, JPH; Wiviott, SD; Yanuv, I	1
Fourlanos, S; Neoh, SL; Nolan, BJ; Varadarajan, S	1
Alper, E; Deyneli, O; Esin, A; Meriçöz, Ç; Sezer, H; Yazıcı, D	1
Ahn, DJ; Lee, IH	1
Gastelum, AA; Latif, A; Reddy, JT; Sood, A	1
Bantis, K; Daikidou, D; Dimitriadis, C; Kasimatis, E; Papagianni, A; Papanikolaou, A; Sampani, E; Sarafidis, P	1
Akamizu, T; Ariyasu, H; Furukawa, Y; Furuta, H; Inaba, H; Iwakura, H; Kishimoto, S; Kitahara, C; Matsuno, S; Morita, S; Nishi, M; Takeshima, K; Uraki, S	1
Chen, R; Li, N; Liu, K	1
Ozer, O; Yorulmaz, G	1
Aaron, M; Collins, SP; Cox, ZL; Davidson, BT; Fowler, M; Hernandez, GA; Iii, ATM; Jenkins, CA; Jr, FEH; Kampe, C; Lindenfeld, J; Lindsell, CJ; Miller, KF; Stubblefield, WB	1
Dashora, U; Dhatariya, K; Gregory, R; Macklin, A; Nagi, D; Patel, DC; Rayman, G; Rowles, S; Winocour, P	1
Chadha, S; Jayasinghe, R; Niranjan, S; Oldfield, K	1
Milanes, L; Voskertchian, A	1
Bourron, O; Hartemann, A; Jeannin, AC; Laroche, S; Phan, F	1
Bilz, S; Brändle, M; Fournier, JY; Quarella, M; Walser, D	1
Aschenbrenner, DS	1
Ahmed, M; Crowley, RK; McKenna, MJ	1
Greenfield, JR; Isaacs, M; Tonks, KT	1
Pereyra A, M; Ramírez, C; Román, R	1
Bailey, CJ; Jabbour, S; Karup, C; Langkilde, AM; Scheen, A; Seufert, J	1
Brown, F; McColl, T	1
Dull, RB; Knezevich, EL; Lau, BM; Spangler, ML	1
Lin, YH	1
Bain, SC; Bashir, J; Chudleigh, R; Nalla, P; Peter, R	1
Akturk, HK; Garg, SK; Rewers, A	1
Ebenbichler, CF; Kempf, P; Laimer, M; Lunger, L; Mader, JK; Melmer, A; Pieber, TR; Stettler, C; Tilg, H	1
Chou, YM; Goh, ZNL; Lin, CC; Seak, CJ; Seak, CK; Seak, JC	1
Acosta-Delgado, D; Hernandez-Quiles, C; Ramirez-Duque, N	1
Athyros, V; Doumas, M; Imprialos, K; Patoulias, D; Stavropoulos, K	1
Henry, RR; McCrimmon, RJ	1
Inzucchi, SE; Lupsa, BC	1
Akyol, PY; Karakaya, Z; Payza, U; Topal, F; Topal, FE	1
Abdul-Ghani, M; DeFronzo, RA; Fawaz, M; Jayyousi, A; Megahed, A; Migahid, O; Singh, R	1
Eliasson, B; Franzén, S; Gudbjörnsdottir, S; Hveem, K; Jonasson, C; Melbye, M; Pasternak, B; Svanström, H; Svensson, AM; Ueda, P	1
Donnan, K; Segar, L	1
Aubrey-Bassler, K; Chibrikov, E; Curnew, D; Donnan, JR; Gamble, JM; Grandy, CA; Hache, J; Johnston, K; Marra, CA; Nguyen, H; Swab, M	1
Boeder, S; Edelman, SV	1
Gilbert, JD; Goldenberg, RM; Hramiak, IM; Woo, VC; Zinman, B	1
Buschur, EO; Buse, JB; Cohan, P; Diner, JC; Hirsch, IB; Peters, AL	1
Blau, JE; Rother, KI; Taylor, SI	1
Bagger, JI; Knop, FK; Rungby, J; Storgaard, H; Vilsbøll, T	1
Bloomgarden, ZT	1
Farooq, S; Islam, N; Kiran, Z; Rashid, O	1
Valek, R; Von der Mark, J	1
Hou, SK; Kao, WF; Li, SJ; Wang, AY	1
Kristensen, FB; Lindberg, MJ; Yildiz, A	1
Ejskjaer, N; Heinemann, L; Klonoff, D; Pfützner, A; Pickup, J	1

Reviews

15 review(s) available for glucose, (beta-d)-isomer and Diabetic Ketoacidosis

Article	Year
A Network Meta-Analysis of the Dose-Response Effects of Dapagliflozin on Efficacy and Safety in Adults With Type 1 Diabetes. Frontiers in endocrinology, 2022, Volume: 13 Topics: Adult; Benzhydryl Compounds; Diabetes Mellitus, Type 1; Diabetic Ketoacidosis; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Network Meta-Analysis	2022
Severe euglycemic diabetic ketoacidosis of multifactorial etiology in a type 2 diabetic patient treated with empagliflozin: case report and literature review. BMC nephrology, 2020, 07-15, Volume: 21, Issue:1 Topics: Acid-Base Equilibrium; Anti-Bacterial Agents; Benzhydryl Compounds; Blood Gas Analysis; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Female; Fluid Therapy; Glucosides; Glycerophosphates; Humans; Hypoglycemic Agents; Hysterectomy; Insulin; Middle Aged; Postoperative Complications; Sodium Bicarbonate; Sodium-Glucose Transporter 2 Inhibitors; Surgical Wound Infection	2020
Sodium-Glucose Cotransporter Inhibitors for the Treatment of Type 1 Diabetes Mellitus. Clinical drug investigation, 2020, Volume: 40, Issue:11 Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 1; Diabetic Ketoacidosis; Glucosides; Humans; Hypoglycemic Agents; Insulin; Sodium-Glucose Transporter 2 Inhibitors	2020
Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials. Diabetes, obesity & metabolism, 2018, Volume: 20, Issue:3 Topics: Adult; Aged; Amputation, Surgical; Benzhydryl Compounds; Blood Volume; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Double-Blind Method; Female; Fractures, Spontaneous; Glomerular Filtration Rate; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Middle Aged; Reproductive Tract Infections; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Urinary Tract Infections	2018
Sodium-glucose cotransporter-2 inhibitors induced eu-glycemic diabetic ketoacidosis: The first report in a type 2 diabetic (T2D) Taiwanese and literature review of possible pathophysiology and contributing factors. Journal of the Formosan Medical Association = Taiwan yi zhi, 2018, Volume: 117, Issue:9 Topics: Administration, Oral; Adult; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Female; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors; Taiwan; Treatment Outcome	2018
SGLT inhibition: a possible adjunctive treatment for type 1 diabetes. Current opinion in endocrinology, diabetes, and obesity, 2018, Volume: 25, Issue:4 Topics: Adult; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Glucosides; Glycosides; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Sodium-Glucose Transporter 2 Inhibitors; Weight Gain	2018
Ketoacidosis Due to Empagliflozin, a Paradigm Shift: Case Report and Review of Literature. Current diabetes reviews, 2019, Volume: 15, Issue:4 Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors	2019
SGLT-2 Inhibitors in Type 1 Diabetes Mellitus: A Comprehensive Review of the Literature. Current clinical pharmacology, 2018, Volume: 13, Issue:4 Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 1; Diabetic Ketoacidosis; Glucosides; Humans; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors	2018
SGLT inhibitor adjunct therapy in type 1 diabetes. Diabetologia, 2018, Volume: 61, Issue:10 Topics: Benzhydryl Compounds; Blood Glucose; Body Weight; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 1; Diabetic Ketoacidosis; Glucosides; Glycosides; Humans; Hypoglycemic Agents; International Cooperation; Multicenter Studies as Topic; Observational Studies as Topic; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 1	2018
Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits. Diabetologia, 2018, Volume: 61, Issue:10 Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Bone and Bones; Canagliflozin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Glucosides; Humans; Hypoglycemic Agents; Ketosis; Kidney; Neoplasms; Randomized Controlled Trials as Topic; Risk Assessment; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Weight Loss	2018
SGLT2 inhibitors and metformin: Dual antihyperglycemic therapy and the risk of metabolic acidosis in type 2 diabetes. European journal of pharmacology, 2019, Mar-05, Volume: 846 Topics: Acidosis, Lactic; Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Drug Therapy, Combination; Glucosides; Humans; Metformin; Risk; Sodium-Glucose Transporter 2 Inhibitors	2019
Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis. BMJ open, 2019, 02-01, Volume: 9, Issue:1 Topics: Acute Kidney Injury; Amputation, Surgical; Benzhydryl Compounds; Canagliflozin; Diabetic Ketoacidosis; Fractures, Bone; Glucosides; Humans; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Urinary Tract Infections	2019
Sodium-glucose co-transporter inhibitors as adjunctive treatment to insulin in type 1 diabetes: A review of randomized controlled trials. Diabetes, obesity & metabolism, 2019, Volume: 21 Suppl 2 Topics: Adult; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Body Weight; Canagliflozin; Diabetes Mellitus, Type 1; Diabetic Ketoacidosis; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome	2019
Sodium-glucose co-transporter inhibitors, their role in type 1 diabetes treatment and a risk mitigation strategy for preventing diabetic ketoacidosis: The STOP DKA Protocol. Diabetes, obesity & metabolism, 2019, Volume: 21, Issue:10 Topics: Benzhydryl Compounds; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 1; Diabetic Ketoacidosis; Glucosides; Humans; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors	2019
SGLT2 Inhibitors May Predispose to Ketoacidosis. The Journal of clinical endocrinology and metabolism, 2015, Volume: 100, Issue:8 Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Disease Susceptibility; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; United States	2015

Trials

4 trial(s) available for glucose, (beta-d)-isomer and Diabetic Ketoacidosis

Article	Year
Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE-TIMI 58 Study. Diabetes care, 2020, Volume: 43, Issue:2 Topics: Adult; Age Factors; Aged; Aged, 80 and over; Aging; Benzhydryl Compounds; Cardiovascular System; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Female; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Incidence; Kidney; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Survival Analysis; Treatment Outcome; Urinary Tract Infections	2020
Efficacy and safety of dapagliflozin in acute heart failure: Rationale and design of the DICTATE-AHF trial. American heart journal, 2021, Volume: 232 Topics: Acute Disease; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Disease Progression; Glucosides; Heart Failure; Hospital Mortality; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Hypotension; Hypovolemia; Insulin; Natriuresis; Natriuretic Peptide, Brain; Patient Readmission; Peptide Fragments; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Weight Loss	2021
Short-term effects of dapagliflozin on insulin sensitivity, postprandial glucose excursion and ketogenesis in type 1 diabetes mellitus: A randomized, placebo-controlled, double blind, cross-over pilot study. Diabetes, obesity & metabolism, 2018, Volume: 20, Issue:11 Topics: Adult; Benzhydryl Compounds; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 1; Diabetic Ketoacidosis; Double-Blind Method; Drug Administration Schedule; Glucosides; Humans; Insulin Resistance; Ketone Bodies; Male; Middle Aged; Pilot Projects; Postprandial Period	2018
Pioglitazone prevents the increase in plasma ketone concentration associated with dapagliflozin in insulin-treated T2DM patients: Results from the Qatar Study. Diabetes, obesity & metabolism, 2019, Volume: 21, Issue:3 Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Drug Therapy, Combination; Exenatide; Female; Glucosides; Humans; Insulin; Ketones; Male; Middle Aged; Pioglitazone; Qatar; Treatment Outcome	2019

Other Studies

39 other study(ies) available for glucose, (beta-d)-isomer and Diabetic Ketoacidosis

Article	Year
Euglycemic Diabetic Ketoacidosis After Cardiac Surgery in a Patient Treated With Empagliflozin for Type 2 Diabetes Mellitus. Journal of cardiothoracic and vascular anesthesia, 2022, Volume: 36, Issue:7 Topics: Benzhydryl Compounds; Cardiac Surgical Procedures; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Glucosides; Humans	2022
Case Report: High-Calorie Glucose Infusion and Tight Glycemic Control in Ameliorating Refractory Acidosis of Empagliflozin-Induced Euglycemic Diabetic Ketoacidosis. Frontiers in endocrinology, 2022, Volume: 13 Topics: Benzhydryl Compounds; Diabetes Mellitus; Diabetic Ketoacidosis; Glucose; Glucosides; Glycemic Control; Humans; Sodium-Glucose Transporter 2 Inhibitors	2022
The incidence of diabetic ketoacidosis associated with empagliflozin use in Aotearoa New Zealand: a preliminary review. The New Zealand medical journal, 2022, 05-20, Volume: 135, Issue:1555 Topics: Benzhydryl Compounds; Diabetes Mellitus; Diabetic Ketoacidosis; Glucosides; Humans; Incidence; New Zealand	2022
Euglycaemic diabetic ketoacidosis in a patient with pancreatitis and type 2 diabetes on empagliflozin. BMJ case reports, 2022, Jun-22, Volume: 15, Issue:6 Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Glucosides; Humans; Male; Pancreatitis; Sodium-Glucose Transporter 2 Inhibitors	2022
A Case of Euglycemic Diabetic Ketoacidosis due to Empagliflozin Use in a Patient with Type 1 Diabetes Mellitus. Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 2022, Volume: 32, Issue:7 Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 1; Diabetic Ketoacidosis; Female; Glucosides; Humans; Sodium-Glucose Transporter 2 Inhibitors	2022
Euglycemic diabetic ketoacidosis after the initiation of dulaglutide in patient with type 2 diabetes. Medicine, 2023, Jun-09, Volume: 102, Issue:23 Topics: Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Glucose; Glucosides; Humans; Male; Middle Aged; Sodium; Sodium-Glucose Transporter 2 Inhibitors; Symporters	2023
Dapagliflozin (SGLT2-i) induced euglycaemic diabetic ketoacidosis. BMJ case reports, 2019, Sep-19, Volume: 12, Issue:9 Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Female; Glucosides; Humans; Hyperglycemia; Kidney Tubules, Proximal; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors	2019
[Risk of Euglycemic Diabetic Ketoacidosis Due to Low-carbohydrate Diet While Taking Empagliflozin: a Case Report]. Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 2019, Volume: 139, Issue:11 Topics: Benzhydryl Compounds; Diabetic Ketoacidosis; Diet, Carbohydrate-Restricted; Glucose; Glucosides; Humans; Insulin; Isotonic Solutions; Male; Middle Aged; Risk; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome	2019
Melatonin ameliorates SGLT2 inhibitor-induced diabetic ketoacidosis by inhibiting lipolysis and hepatic ketogenesis in type 2 diabetic mice. Journal of pineal research, 2020, Volume: 68, Issue:2 Topics: Animals; Benzhydryl Compounds; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Glucosides; Lipolysis; Male; Melatonin; Mice; Signal Transduction; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors	2020
Beware Ketoacidosis with SGLT2 Inhibitors in Latent Autoimmune Diabetes of the Adult. The American journal of medicine, 2020, Volume: 133, Issue:8 Topics: Aged; Autoantibodies; Benzhydryl Compounds; Diabetic Ketoacidosis; Female; Fluid Therapy; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Ketosis; Latent Autoimmune Diabetes in Adults; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors	2020
Empagliflozin-induced ketoacidosis in a patient presenting with new-onset type 2 diabetes mellitus due to indolent pancreatic cancer. Endokrynologia Polska, 2020, Volume: 71, Issue:3 Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Pancreatic Neoplasms	2020
Dapagliflozin-associated euglycemic diabetic ketoacidosis in a patient with type 2 diabetes mellitus: A case report. Medicine, 2020, May-22, Volume: 99, Issue:21 Topics: Administration, Intravenous; Aged; Anti-Bacterial Agents; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Female; Fluid Therapy; Glucosides; Humans; Hypernatremia; Hypoglycemic Agents; Hypokalemia; Insulin; Intestinal Pseudo-Obstruction; Kidney Pelvis; Metformin; Patient Discharge; Sodium-Glucose Transporter 2 Inhibitors; Ureter; Withholding Treatment	2020
Euglycaemic diabetic ketoacidosis in a 43-year-old woman with type 2 diabetes mellitus on SGLT-2 inhibitor (empagliflozin). BMJ case reports, 2020, Jun-07, Volume: 13, Issue:6 Topics: Adult; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Diagnosis, Differential; Diet, Ketogenic; Female; Fluid Therapy; Glucosides; Humans; Hypoglycemic Agents; Insulin; Sodium-Glucose Transporter 2; Time-to-Treatment	2020
Early detection of euglycemic ketoacidosis during thoracic surgery associated with empagliflozin in a patient with type 2 diabetes: A case report. Journal of diabetes investigation, 2021, Volume: 12, Issue:4 Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Glucosides; Humans; Intraoperative Complications; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Thoracic Surgical Procedures	2021
Euglycemic Diabetic Ketoacidosis Associated with Empagliflozin Use in the Course of the SARS-Cov-2 Pandemic. Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 2020, Volume: 30, Issue:10 Topics: Adult; Benzhydryl Compounds; Betacoronavirus; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Diagnosis, Differential; Female; Glucosides; Humans; Pandemics; Pneumonia, Viral; SARS-CoV-2; Sodium-Glucose Transporter 2 Inhibitors	2020
Association of British Clinical Diabetologists (ABCD) and Diabetes UK joint position statement and recommendations on the use of sodium-glucose cotransporter inhibitors with insulin for treatment of type 1 diabetes (Updated October 2020). Diabetic medicine : a journal of the British Diabetic Association, 2021, Volume: 38, Issue:2 Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 1; Diabetic Ketoacidosis; Drug Therapy, Combination; Glucosides; Glycosides; Humans; Hypoglycemic Agents; Insulin; Overweight; Practice Guidelines as Topic; Sodium-Glucose Transporter 2 Inhibitors; United Kingdom	2021
Immune checkpoint inhibitor-induced takotsubo syndrome and diabetic ketoacidosis: rare reactions. BMJ case reports, 2021, Feb-01, Volume: 14, Issue:2 Topics: Aged; Benzhydryl Compounds; Brain Neoplasms; Coronary Angiography; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Echocardiography; Glucosides; Humans; Immune Checkpoint Inhibitors; Ipilimumab; Magnetic Resonance Imaging; Male; Melanoma; Nivolumab; Sodium-Glucose Transporter 2 Inhibitors; Takotsubo Cardiomyopathy	2021
Case Report: DKA with Lower-than-Expected Blood Glucose in the Setting of SGLT2 Inhibitor Use. American family physician, 2021, 02-15, Volume: 103, Issue:4 Topics: Adamantane; Benzhydryl Compounds; Blood Glucose; Diabetic Ketoacidosis; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucosides; Humans; Hypoglycemic Agents; Insulin Glargine; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome	2021
Euglycaemic diabetic ketosis decompensation under dapagliflozin in a patient with MODY3. Diabetes & metabolism, 2021, Volume: 47, Issue:6 Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Glucosides; Humans	2021
Rapid Onset of Diabetic Ketoacidosis After SGLT2 Inhibition in a Patient With Unrecognized Acromegaly. The Journal of clinical endocrinology and metabolism, 2017, 05-01, Volume: 102, Issue:5 Topics: Adenoma; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Drug Therapy, Combination; Fatty Acids, Nonesterified; Gliclazide; Glucagon; Glucosides; Growth Hormone-Secreting Pituitary Adenoma; Humans; Hypoglycemic Agents; Insulin; Ketone Bodies; Male; Metformin; Middle Aged; Severity of Illness Index; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors	2017
Diabetes Drug Receives New Indication. The American journal of nursing, 2017, Volume: 117, Issue:4 Topics: Acute Kidney Injury; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Drug Labeling; Drug Repositioning; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors	2017
DIABETIC KETOACIDOSIS IN PATIENTS WITH TYPE 2 DIABETES RECENTLY COMMENCED ON SGLT-2 INHIBITORS: AN ONGOING CONCERN. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2017, 04-02, Volume: 23, Issue:4 Topics: Aged; Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Patient Education as Topic; Patient Selection; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors	2017
Euglycaemic diabetic ketoacidosis in patients using sodium-glucose co-transporter 2 inhibitors. Internal medicine journal, 2017, Volume: 47, Issue:6 Topics: Aged, 80 and over; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Female; Glucosides; Humans; Male; Middle Aged; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors	2017
[Euglycemic ketosis in an adolescent with type 1 diabetes on insulin and dapaglifozin: Case report]. Revista chilena de pediatria, 2017, Volume: 88, Issue:3 Topics: Adolescent; Benzhydryl Compounds; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 1; Diabetic Ketoacidosis; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemic Agents; Insulin	2017
Euglycemic Diabetic Ketoacidosis Secondary to Dapagliflozin Use: A Case Report. The Journal of emergency medicine, 2018, Volume: 54, Issue:1 Topics: Abdominal Pain; Anorexia; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Glucosides; Humans; Hyperglycemia; Male; Middle Aged; Sodium-Glucose Transporter 2; Vomiting	2018
Euglycemic Diabetic Ketoacidosis Associated With Sodium-Glucose Cotransporter Type 2 Inhibitors in Patients With Type 2 Diabetes Mellitus Receiving Oral Therapy. Journal of pharmacy practice, 2019, Volume: 32, Issue:2 Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Female; Glucosides; Humans; Hypoglycemic Agents; Infections; Insulin; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors	2019
A case series of DKA occurring in patients receiving treatment with SGLT-2 inhibitors. Diabetes, obesity & metabolism, 2018, Volume: 20, Issue:7 Topics: Adult; Aged; Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Female; Glucosides; Humans; Latent Autoimmune Diabetes in Adults; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; United Kingdom	2018
Euglycemic diabetic ketoacidosis caused by dapagliflozin: A case report. Medicine, 2018, Volume: 97, Issue:25 Topics: Abdominal Pain; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Dyspnea; Fatigue; Female; Glucosides; Humans; Hypoglycemic Agents; Middle Aged; Nausea; Vomiting	2018
Euglisemic diabetic ketoacidotic coma caused by dapagliflozin. The American journal of emergency medicine, 2018, Volume: 36, Issue:11 Topics: Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Coma; Diabetic Ketoacidosis; Female; Glucosides; Humans; Sodium-Glucose Transporter 2 Inhibitors	2018
Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study. BMJ (Clinical research ed.), 2018, Nov-14, Volume: 363 Topics: Adult; Amputation, Surgical; Benzhydryl Compounds; Canagliflozin; Cohort Studies; Denmark; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Female; Fractures, Bone; Glucosides; Humans; Hypoglycemic Agents; Logistic Models; Male; Middle Aged; Pancreatitis; Propensity Score; Sodium-Glucose Transporter 2 Inhibitors; Sweden; Urinary Tract Infections; Venous Thromboembolism	2018
Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition. Diabetes care, 2015, Volume: 38, Issue:9 Topics: Adult; Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors	2015
Diabetic Ketoacidosis in a Patient with Type 2 Diabetes After Initiation of Sodium-Glucose Cotransporter 2 Inhibitor Treatment. Basic & clinical pharmacology & toxicology, 2016, Volume: 118, Issue:2 Topics: Adult; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Glucosides; Humans; Hypoglycemic Agents; Insulin; Kidney Tubules, Proximal; Male; Medication Therapy Management; Obesity; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome	2016
Sodium-glucose cotransporter 2 inhibitors and diabetic ketoacidosis. Journal of diabetes, 2016, Volume: 8, Issue:2 Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors	2016
Gliflozins: ketoacidosis. Prescrire international, 2016, Volume: 25, Issue:169 Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Glucosides; Humans; Hypoglycemic Agents	2016
Euglycaemic diabetic ketoacidosis in a patient with type 2 diabetes started on empagliflozin. BMJ case reports, 2016, May-13, Volume: 2016 Topics: Adult; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemic Agents; Insulin; Liraglutide; Male; Metformin; Pioglitazone; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidinediones	2016
[Acidosis without marked hyperglycemia : Euglycemic diabetic ketoacidosis associated with SGLT2-Inhibitors]. Medizinische Klinik, Intensivmedizin und Notfallmedizin, 2017, Volume: 112, Issue:2 Topics: Benzhydryl Compounds; Blood Glucose; Combined Modality Therapy; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemic Agents; Insulin Glargine; Male; Metformin; Middle Aged; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors	2017
Euglycemic diabetic ketoacidosis in type 2 diabetes with sodium glucose cotransporter 2 inhibitors. The American journal of emergency medicine, 2017, Volume: 35, Issue:2 Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Female; Glucosides; Humans; Hypoglycemic Agents; Insulin; Middle Aged; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome	2017
[Life-threatening ketoacidosis in a 25-year-old woman treated with sodium-glucose cotransporter 2 inhibitor]. Ugeskrift for laeger, 2016, Nov-21, Volume: 178, Issue:47 Topics: Adult; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Female; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors	2016
Euglycemic ketosis in patients with type 2 diabetes on SGLT2-inhibitor therapy-an emerging problem and solutions offered by diabetes technology. Endocrine, 2017, Volume: 56, Issue:1 Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transport Proteins	2017